ABSTRACT:

This study is the first to examine the possibility of pharmacokinetic interaction in blood circulation using amlodipine and clarithromycin as representatives in hypertension rabbits and identify changes. The current study design required rabbits (n=6) for Pharmacokinetics. In group A, rabbits without treatment were used as control. In group B, were administration of a single dose of amlodipine (0.21mg/kg.BW) for 24 hours. Group C, were administered with a single dose of amlodipine (0.21mg/kg/BW.) and clarithromycin (22 mg/kg/BW.) each 6 hr. for 24 hour. The blood samples were collected from (B and C) groups at time intervals of zero, 1, 2, 3, 4, 6, 8, 12, 24, 36, 48, 60, 72, 96, 120, 144 hours and the drug concentrations were estimated using a spectrophotometer and estimated blood pressure using blood pressure cuff with Doppler ultrasound transducer. An increase in C max and AUC in group C (3.52 μg/ml and 130 μg/ml*h) respectively, indicates the  improved bioavailability of amlodipine in the presence of clarithromycin compared with group B (2.03 μg/ml and 96.10 μg/ml*h) respectively. Furthermore, reduction in (CL) with an elevation of (Vd) in the presence of clarithromycin (54.94 L/kg/hr. and 4994 L/kg) in group C respectively, compared with group B (74.31 L/kg/hr and 3715 L/kg) respectively. We studied the influence of clarithromycin on the pharmacodynamics of amlodipine in hypertension rabbits. Interaction of amlodipine with multiple doses of clarithromycin produced a high reduction in blood pressure at 9 after administration and the blood pressure continues redaction. In conclusion, the combination of amlodipine with clarithromycin led to the enhancement of the bioavailability of amlodipine by inhibiting the CYP3A4 enzyme leading to producing a hypotension effect with peak plasma concentration effect in hypertension rabbits.

REFERENCES :

1) Ahsan, S. F., & Khan, M. F. (2017). MINI REVIEW PHYSICOCHEMICAL PROPERTIES AND PHARMACOLOGY OF AMLODIPINE BESYLATE : A BRIEF REVIEW, 20(2), 9–12.
2) Chavers BM, Solid CA, Gilbertson DT, Collins AJ.(2007). Infection-related hospitalization rates in pediatric versus adult patients with cytochrome end _stage renal disease in the United States. J is Soc Nephrol 18:952-9.
3) Chudow, M., & Ferguson, K. (2018). A Case of Severe, Refractory Hypotension After Amlodipine Overdose. Cardiovascular Toxicology, 18(2), 192–197.

https://doi.org/10.1007/s12012-017-9419-x.
4) Fohner, A. E., Sparreboom, A., Altman, R. B., & Klein, T. E. (2017). PharmGKB summary: Macrolide antibiotic pathway, pharmacokinetics/ pharmacodynamics. Pharmacogenetics and genomics, 27(4), 164.
5) Gandhi, S., Fleet, J. L., Bailey, D. G., McArthur, E., Wald, R., Rehman, F., & Garg, A. X. (2013). Calcium-channel blockerclarithromycin drug interactions and acute kidney injury. JAMA – Journal of the American Medical Association, 310(23), 2544–2553.

https://doi.org/10.1001/jama.2013.282426.
6) Hayes, C. L. (2018). An Update on Calcium Channel Blocker Toxicity in Dogs and Cats. Veterinary Clinics of North America – Small Animal Practice, 48(6), 943–957.

https://doi.org/10.1016/j.cvsm.2018.06.002
7) Janadri, S.; Ramachandra, S.S. and Kharya, M.D. (2009). Influence of itraconazole on the antidiabetic effect of thiazolidinedione in diabetic rats. International Journal of Pharmacy and Pharmaceutical Sciences, 1(1): 119-24.
8) Johnson, R., Dludla, P., Mabhida, S., Benjeddou, M., Louw, J., & February, F. (2019). Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini-review. Heart Failure Reviews.
https://doi.org/10.1007/s10741-018-09765-y
9) Kader, Ç., Ede, H., Erbay, A., & Erbay, A. (2015). Drug interaction of bocepravir and amlodipine in a patient with hepatitis C: A Cardiovascular follow-up. Journal of Microbiology and Infectious Diseases, 5(01), 32–35.
https://doi.org/10.5799/ahinjs.02.2015.01.0172.
10) Kim, B. K., Lee, H. W., Yoon, Y.-R., La, S., Ohk, B., Gwon, M.-R., … Cho, S. (2018). Pharmacokinetic and bioequivalence study of a telmisartan/S-amlodipine fixed-dose combination (CKD-828) formulation and coadministered telmisartan and S-amlodipine in healthy subjects. Drug Design, Development and Therapy, Volume 12, 545–553.
https://doi.org/10.2147/dddt.s156492.
11) Matheny, C.J.; Lamb, M.W.; Brouwer, K.L. and Pollack, G.M. (2001). Pharmacokinetic and pharmacodynamics implications of P‐glycoprotein modulation. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 21(7): 778-796.
12) May, M. and Schindler, C. (2016). Clinically and pharmacologically relevant interactions of antidiabetic drugs. Therapeutic advances in endocrinology and metabolism, 7(2): 69-83.
13) Ohmori, S.; Ishii, I.; Kuriya, S.; Taniguchi, T.; Rikihisa, T.; Hirose, S. and Kitada, M. U. (1993). Effects of clarithromycin and its metabolites on the mixed function oxidase system in hepatic microsomes of rats. Drug Metabolism And Disposition, 21(2): 358-363
14) Oyedi Kofi, J., Janet Oyedi Kofi, A., & Marja-Liisa Hiironen, S. (2011). PREVENTION AND MANAGEMENT OF HYPERTENSION: A study on knowledge and attitudes of women of childbearing age Thesis CENTRAL OSTROBOTHNIA UNIVERSITY OF APPLIED SCIENCES Degree Programme in Nursing,(September). Retrieved from
https://www.theseus.fi/bitstream/handle/10024/41325/Kofi_Janet pdf
15) Parameshappa, B.; Rao, N.V.; Gouda, T.S.; Sen, S.; Chakraborty, R.; Basha, M.A. and Kumar, S.S. (2010). A study on drug-drug interaction between anti-hypertensive drug (propranolol) and anti-diabetic drug (glipizide). Annals of Biological Research, 1(3): 35-40.
16) Pinto, V. L., Wenderfer, S. E., Morris, J., & Akcan-Arikan, A. (2019). Treatment of Severe Amlodipine Toxicity With Molecular Adsorbent Recirculating System. Kidney International Reports, 4(2), 346–349. https://doi.org/10.1016/j.ekir.2018.09.017
17) Srinivasulu, P., Gowthami, B. K., Kumar, T. N. V. G., Raju, D. S. N., & Vidyadhara, S. (2015). Determination of Amlodipine in Rat Plasma by UV Spectroscopy, 5(3), 205–209.
18) Theodosios, D.F.; Evangelos, N.L. and Moses, S.E. (2015). Dapagliflozin in patients with type 2 diabetes mellitus. TherAdv Endocrinol Metab., 6(1): 29-41.
19) Tornio, A.; Niemi, M.; Neuvonen, P.J. and Backman, J.T. (2012). Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications. Trends In Pharmacological Sciences, 33(6): 312-322.
20) Wright, A. J., Mhsc, T. G., Mamdani, M. M., Mph, P., & Pharmd, J. R. H. (2011). Macrolide Antibiotics and CalciumChannel Blockers, 183(3), 1–5.
21) Zhu, Y., Wang, F., Li, Q., Zhu, M., Du, A., Tang, W., & Chen, W. (2014). Amlodipine metabolism in human liver microsomes and roles of CYP3A4/5 in the dihydropyridine dehydrogenation. Drug Metabolism and Disposition, 42(2), 245–249.

https://doi.org/10.1124/dmd.113.055400.